First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study

Aogi, Kenjiro; Masuda, Norikazu; Ohno, Shinji; Oda, Takashi; Iwata, Hiroji; Kashiwaba, Masahiro; Fujiwara, Yasuhiro; Kamigaki, Shunji; Ito, Yoshiaki; Ueno, Takayuki; Takashima, Shigemitsu

doi:10.1007/s10549-011-1685-x

Cited by 42 publications

(30 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present trial, the combination schedule of bevacizumab and paclitaxel as reported by Miller et al [1] resulted in a median PFS of 8.6 months, which was slightly shorter than the reported median PFS varying between 9.2 and 12.9 months obtained in the E2100 [1] and other phase II/III trials [21][22][23] of first-line paclitaxel plus bevacizumab (Appendix p. [15][16]. The precise reason for this discrepancy remains speculative.…”

Section: Discussioncontrasting

confidence: 47%

See 1 more Smart Citation

Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial

Lam

Groot

Honkoop

et al. 2014

European Journal of Cancer

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 47%

“…The PFS rate at one year was 42% (95% CI 35-51) for ATX and 21% (95% CI [16][17][18][19][20][21][22][23][24][25][26][27][28][29] for AT.…”

Section: Efficacymentioning

confidence: 99%

Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial

Lam

Groot

Honkoop

et al. 2014

European Journal of Cancer

View full text Add to dashboard Cite

“…However, unlike the results seen in the ovarian cancer setting, late-onset hypertension was remarkably infrequent in patients receiving bevacizumab for prolonged periods. In the single-arm JO19901 study, in which 120 Japanese patients received first-line bevacizumab in combination with paclitaxel for mBC, only a small number of patients developed proteinuria or hypertension in later cycles [13].…”

Section: Discussionmentioning

confidence: 99%

Final overall survival results and effect of prolonged (≥1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial

Smith

Pierga

Biganzoli

et al. 2011

Breast Cancer Res Treat

View full text Add to dashboard Cite

The ATHENA study expanded on the safety and efficacy data derived from first-line trials of bevacizumab combined with standard chemotherapy for locally recurrent/metastatic breast cancer (LR/mBC). In ATHENA, 2,264 patients received first-line bevacizumab-containing therapy in routine oncology practice. Overall survival (OS) data are now mature; additional analyses from this large data set can provide insights into treatment duration and the effect of prolonged bevacizumab exposure, where data are currently limited. Patients with HER2-negative LR/mBC received first-line bevacizumab with standard chemotherapy until disease progression, unacceptable toxicity, or physician/patient decision. We performed subgroup analyses on data from patients treated for ≥12 months and those who continued single-agent bevacizumab after stopping chemotherapy. After median follow-up of 20.1 months, median OS was 25.2 months (95% confidence interval [CI] 24.0-26.3 months) in the entire population. Median OS was 30.0 months (95% CI 28.5-32.7 months) in 1,205 patients who continued bevacizumab after discontinuation of chemotherapy and 18.4 months (95% CI 17.2-19.7 months) in 1,058 patients who discontinued bevacizumab before or at the same time as stopping chemotherapy. Bevacizumab treatment was continued for ≥12 months in 473 patients (21%). In most, bevacizumab was administered as monotherapy for extended periods after stopping chemotherapy. In the subgroup of patients treated for ≥12 months, the median time to onset of grade 3-5 adverse events was 5.0 months. There was no evidence that first onset of adverse events of special interest, except for proteinuria, was more common in later than earlier cycles. No relationship was detected between development of hypertension and OS. Findings from these analyses suggest that patients with LR/mBC can receive bevacizumab for prolonged periods without major toxicity or progression of disease. In the absence of progression, continuation of single-agent bevacizumab appears to be a reasonable approach, with minimal toxicity and the possibility of long-term disease control.

show abstract

“…Furthermore, the BP regimen showed a shorter median OS of 15.4 months compared with 35.8 months in a study of first-line combined therapy with bevacizumab and paclitaxel in Japan 5 .…”

Section: Safetymentioning

confidence: 94%

A Real-World Retrospective Cohort Study of Combined Therapy with Bevacizumab and Paclitaxel in Japanese Patients with Metastatic Breast Cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study

Cited by 42 publications

References 39 publications

Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial

Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial

Final overall survival results and effect of prolonged (≥1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial

A Real-World Retrospective Cohort Study of Combined Therapy with Bevacizumab and Paclitaxel in Japanese Patients with Metastatic Breast Cancer

Contact Info

Product

Resources

About